Trial · NCT00268996
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Circulating High Sensitivity C- Reactive Protein (Hs-CRP) Levels at Week 52. | Placebo | 1.034 | 95% Confidence Interval 0.854 to 1.251 | mg per litre (mg/L) | |
| Mean Circulating High Sensitivity C- Reactive Protein (Hs-CRP) Levels at Week 52. | Darapladib 160 mg EC Tablet | 0.913 | 95% Confidence Interval 0.765 to 1.090 | mg per litre (mg/L) | |
Change From Baseline in the Density of Rotterdam Classification (ROC) Grade III/IV Strain Spots/10 Millimeter (mm) Within the Region of Interest (ROI) on IVUS Grey Scale Based Palpography at the End of Week 52. | Placebo | 0.003 | Standard Error 0.048 | Spots/10 mm | |
Change From Baseline in the Density of Rotterdam Classification (ROC) Grade III/IV Strain Spots/10 Millimeter (mm) Within the Region of Interest (ROI) on IVUS Grey Scale Based Palpography at the End of Week 52. | Darapladib 160 mg EC Tablet | -0.079 | Standard Error 0.045 | Spots/10 mm | |
| Circulating Hs-CRP at the End of Week 26. | Placebo | 0.924 | 95% Confidence Interval 0.774 to 1.102 | mg/L | |
| Circulating Hs-CRP at the End of Week 26. | Darapladib 160 mg EC Tablet | 0.960 | 95% Confidence Interval 0.815 to 1.131 | mg/L | |
| Mean Lipoprotein Phospholipase A2 (Lp-PLA2) Activity at the End of Week 26 and Week 52 | Placebo | Week 26 LOCF | 151.412 | 95% Confidence Interval 143.592 to 159.657 | micromole per minute per Litre |
| Mean Lipoprotein Phospholipase A2 (Lp-PLA2) Activity at the End of Week 26 and Week 52 | Darapladib 160 mg EC Tablet | Week 26 LOCF | 59.449 | 95% Confidence Interval 56.591 to 62.452 | micromole per minute per Litre |
| Mean Lipoprotein Phospholipase A2 (Lp-PLA2) Activity at the End of Week 26 and Week 52 | Placebo | Week 52 LOCF | 152.061 | 95% Confidence Interval 144.109 to 160.452 | micromole per minute per Litre |
| Mean Lipoprotein Phospholipase A2 (Lp-PLA2) Activity at the End of Week 26 and Week 52 | Darapladib 160 mg EC Tablet | Week 52 LOCF | 61.850 | 95% Confidence Interval 58.838 to 65.015 | micromole per minute per Litre |
| Change From Baseline in Plaque Volume as IVUS-Grey Scale Assessments at Week 52 | Placebo | -5.126 | Standard Error 2.715 | Cubic millimetre (mm^3) | |
| Change From Baseline in Plaque Volume as IVUS-Grey Scale Assessments at Week 52 | Darapladib 160 mg EC Tablet | -4.873 | Standard Error 2.464 | Cubic millimetre (mm^3) | |
| Change From Baseline in Percent Obstruction Volume as IVUS-Grey Scale Assessments at Week 52 | Placebo | 0.007 | Standard Error 0.354 | Percentage of mm^3 | |
| Change From Baseline in Percent Obstruction Volume as IVUS-Grey Scale Assessments at Week 52 | Darapladib 160 mg EC Tablet | -0.054 | Standard Error 0.321 | Percentage of mm^3 | |
| Change From Baseline in Necrotic Core Volume as Intravenous Ultrasound-Virtual Histology (IVUS-VH) Assessments at Week 52 | Placebo | 4.633 | Standard Error 1.491 | mm^3 | |
| Change From Baseline in Necrotic Core Volume as Intravenous Ultrasound-Virtual Histology (IVUS-VH) Assessments at Week 52 | Darapladib 160 mg EC Tablet | -0.531 | Standard Error 1.376 | mm^3 | |
| Change From Baseline in Necrotic Core as a Percent of IVUS-VH Plaque at the End of Week 52. | Placebo | 2.502 | Standard Error 0.722 | Percent Necrotic core | |
| Change From Baseline in Necrotic Core as a Percent of IVUS-VH Plaque at the End of Week 52. | Darapladib 160 mg EC Tablet | 0.535 | Standard Error 0.666 | Percent Necrotic core | |
| Mean Interlukin 6 (IL-6) Levels as Circulating Biomarkers Associated With Inflammatory Burden at Week 26 and Week 52 | Placebo | Week 26 LOCF | 1.851 | 95% Confidence Interval 1.609 to 2.128 | Nanograms per litre (ng/L) |
| Mean Interlukin 6 (IL-6) Levels as Circulating Biomarkers Associated With Inflammatory Burden at Week 26 and Week 52 | Darapladib 160 mg EC Tablet | Week 26 LOCF | 1.979 | 95% Confidence Interval 1.741 to 2.250 | Nanograms per litre (ng/L) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00268996/results